Charlotte Robinson

DocwireNews

Corticosteroids may be utilized in high-risk patients with immunoglobulin A nephropathy (IgAN) who have greater than 1 g/d of proteinuria despite receiving maximal supportive care.Results of the Therapeutic Effects of Steroids in IgA Nephropathy Global (TESTING) study reported in 2022 found that methylprednisolone reduces the risk of major kidney events in patients with IgAN at high risk of disease progression compared to supportive care alone. However, the drug is associated with an increase in serious adverse events (SAEs), mainly with full-dose therapy.It is important to understand the risks versus benefits of a reduced-dose methylprednisolone regimen to inform the safe use of corticosteroids in clinical practice. In Kidney International Reports, Dana Kim, MBBS, FRACP, and colleagues reported findings of a prespecified secondary analysis of the TESTING study evaluating the safety and efficacy of a reduced-dose oral methylprednisolone regimen in patients with IgAN at a high risk of kidney function decline.The reduced-dose study included participants aged 18 years and older with biopsy-confirmed primary IgAN, an eGFR between 30 and 120 ml/min per 1.73 m2, and a 24-hour urinary protein excretion greater than or equal to 1 g/d despite having received 3 months of maximum tolerated renin-angiotensin system inhibitor therapy.Between 2017 and 2019, 241 patients were randomized to reduced-dose methylprednisolone 0.4 mg/kg/d or placebo. The mean participant age was 37 years, mean baseline eGFR was 65 ml/min per 1.73 m2, and mean 24-hour protein excretion was 2.48 g/d. The median follow-up was 2.5 years. The primary study outcome was a composite of a 40% decline in eGFR, kidney failure, or death due to kidney disease.The researchers found that methylprednisolone was associated with fewer primary outcome events than the placebo (7/121 vs 22/120; HR, 0.24; 95% CI, 0.10-0.58; P=.002). In addition, methylprednisolone reduced the rate of eGFR decline and lowered proteinuria from baseline. The mean difference between methylprednisolone and placebo in proteinuria and eGFR from baseline was -1.15 g/d and 7.9 ml/min per 1.73 m2 (P &lt;.001) at 12 months, respectively. However, these positive effects did not last over time. By 4 years of follow-up, no apparent difference between the groups was observed.Finally, seven SAEs occurred in the methylprednisolone group compared to three in the placebo group (HR, 1.97; 95% CI, 0.49&ndash;7.90). This included five infections in the methylprednisolone group and two in the placebo group.&ldquo;In conclusion,&rdquo; the authors stated, &ldquo;the reduced-dose TESTING study demonstrates that a 6- to 9-month reduced-dose methylprednisolone regimen is associated with improved kidney outcomes and a delay in the progression toward kidney failure for individuals with high-risk IgAN already established on maximal supportive care. However, some increased risk of SAEs likely remains, albeit at a lower rate than with the full-dose regimen.&rdquo;Source: <a href="https://doi.org/10.1016/j.ekir.2024.03.032" target="_blank" rel="noopener">Kidney International Reports</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Reduced-Dose Methylprednisolone Efficacy and Safety in High-Risk IgAN

It is important to understand the risks versus benefits of a reduced-dose methylprednisolone regimen in high-risk IgA nephropathy (IgAN) patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe